Yazar "Demir, Canan" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Circulating irisin levels reflect visceral adiposity in non-diabetic patients undergoing hemodialysis
    (Taylor & Francis Ltd, 2016) Yilmaz, Hakki; Cakmak, Muzaffer; Darcin, Tahir; Inan, Osman; Sahiner, Enes; Demir, Canan; Aktas, Aynur
    Background: Recent evidence suggests that increased visceral adiposity is a strong independent risk factor for cardiovascular death and all-cause mortality in hemodialysis (HD) patients. Irisin, which is a novel myokine, can play critical roles in diabetes and adiposity. The purpose of our study was to investigate whether serum irisin levels are associated with body mass index, waist circumference (WC), and total fat mass in non-diabetic patients undergoing maintenance HD.Methods: This cross-sectional study included 108 non-diabetic HD patients and 40 age- and sex-matched apparently healthy subjects. Serum irisin concentrations were determined using an enzyme-linked immunosorbent assay. Body fat composition (TBF-410 Tanita Body Composition Analyzer) was measured and calculated.Results: Serum irisin levels did not differ between HD patients and the healthy controls (523.50 +/- 229.32 vs. 511.28 +/- 259.74, p=0.782). Serum irisin levels were associated with age (r=0.314; p=0.006), HOMA-IR (r=0.472; p=0.003), WC (r=0.862; p<0.001), and total fat mass (r=0.614; p<0.001). In multivariate regression analysis, WC (=1.240, p<0.001) and total fat mass (=0.792, p=0.015) were the variables that were significantly associated with irisin concentrations (R-2=0.684, p<0.001) after adjusting for confounding factors (age and HOMA-IR). Conclusions: These results suggest that serum irisin levels are related to visceral adiposity in non-diabetic HD patients.
  • Küçük Resim Yok
    Öğe
    Role of interlekin-35 as a biomarker in patients with newly diagnosed hashimoto’s thyroiditis
    (Institute of Experimental Endocrinology macvetrev@fvm.ukim.edu.mk, 2016) Yilmaz, Hakki; Çakmak, Muzaffer; Ceydilek, Bilge; Demir, Canan; Aktas, Aynur
    Objective. Interleukin-35 (IL-35), an interleukin-12 (IL-12) cytokine family member, is shown to be a potent immunosuppressive and anti-inflammatory cytokine. Inducible regulatory T cells (Tregs) produce IL-35 that mediates the immune inhibitory function of Tregs. Growing evidence revealed that upregulation of IL-35 expression may play a critical role in the prevention of autoimmune diseases in various experimental autoimmunity models and vice versa. Hashimoto’s thyroiditis (HT) is considered to be a Treg cell-related autoimmune disease with loss of self-tolerance. Methods. One hundred-twenty eight subjects, newly diagnosed hypothyroid HT patients [56 overt (Group 1), 72 subclinical hypothyroid (Group 2)] and 38 healthy controls (Group 3) were enrolled in the study. The levels of serum IL-35 were determined by enzyme-linked immunosor-bent assay (ELISA). Results. Serum IL-35 levels were lower in the HT group when compared with subclinical HT group [304.5 (834.6) pg/ml vs. 636.1 (1542.0) pg/ml, p=0.004] and control cases [304.5 (834.6) pg/ml vs. 1064.7 (2526.8) pg/ml, p<0.001]. Serum IL-35 levels were inversely associated with thyroid stimulating hormone (TSH; rs=–0.396, p<0.001) and anti-thyroid peroxidase antibodies (TPOAb; rs=–0.571, p<0.001) in whole group. Serum IL-35 were negatively associated with TSH (rs=–0.264, p=0.003) and TPOAb (rs=–0.735, p<0.001) in patients with Hashimoto’s thyroiditis (Group 1 + Group 2). Conclusion. The results suggest that IL-35 may play a role in the pathogenesis of HT. © 2020 Elsevier B.V., All rights reserved.